Other Events ·
On July 23, 2026, Aprea Therapeutics received notification from Nasdaq that it remains non-compliant with the $1.00…
APREAprea Therapeutics, Inc.
On July 23, 2026, Aprea Therapeutics received notification from Nasdaq that it remains non-compliant with the $1.00 minimum bid price requirement. The company has been granted an additional 180-calendar day extension, until January 19, 2027, to regain compliance. To avoid delisting, the common stock's closing bid price must be at least $1.00 for 10 consecutive business days within this period. Aprea Therapeutics is a biopharmaceutical company that develops therapies for rare diseases.